Compare Adaptive Biotechnologies Corp (ADPT) vs e l f Beauty Inc (ELF) Price & Performance

ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.

Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.

ELF Beauty trades at $73.49, down 3.83% recently, but maintains a bullish technical outlook with strong support at $72. The company reported impressive earnings beats in recent quarters with Q4 2025 EPS of $1.24 beating expectations of $0.73. Revenue growth remains robust at $1.31 billion in 2025, though net margins are thin at 1.61%. Analyst sentiment is mixed with 46% buy ratings and a consensus price target of $72.82, slightly below current levels.

The stock faces valuation concerns with a high P/E of 173.68, but strong revenue growth and expansion into haircare and skincare categories provide upside potential. Key risks include tariff exposure and core brand momentum challenges. Institutional ownership trends and recent insider activity suggest cautious optimism as the company executes its diversification strategy.